XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.21.2

REVENUE (Tables) | 9 Months Ended
--- | ---
Jul. 31, 2021
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:
| Three Months Ended July 31
| 2021 |  | 2020
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 226 |  |  | $ | 193 |  |  | $ | 187 |  |  | $ | 606 |  |  | $ | 174 |  |  | $ | 156 |  |  | $ | 121 |  |  | $ | 451 |
Europe | 155 |  |  | 157 |  |  | 111 |  |  | 423 |  |  | 111 |  |  | 127 |  |  | 84 |  |  | 322 |
Asia Pacific | 299 |  |  | 210 |  |  | 48 |  |  | 557 |  |  | 272 |  |  | 180 |  |  | 36 |  |  | 488 |
Total | $ | 680 |  |  | $ | 560 |  |  | $ | 346 |  |  | $ | 1,586 |  |  | $ | 557 |  |  | $ | 463 |  |  | $ | 241 |  |  | $ | 1,261 |
| Nine Months Ended July 31
| 2021 |  | 2020
| Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total |  | Life Sciences and Applied Markets |  | Agilent CrossLab |  | Diagnostics and Genomics |  | Total
| (in millions)
Revenue by Region |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 681 |  |  | $ | 559 |  |  | $ | 502 |  |  | $ | 1,742 |  |  | $ | 553 |  |  | $ | 484 |  |  | $ | 365 |  |  | $ | 1,402 |
Europe | 500 |  |  | 458 |  |  | 317 |  |  | 1,275 |  |  | 389 |  |  | 391 |  |  | 268 |  |  | 1,048 |
Asia Pacific | 895 |  |  | 611 |  |  | 136 |  |  | 1,642 |  |  | 779 |  |  | 507 |  |  | 120 |  |  | 1,406 |
Total | $ | 2,076 |  |  | $ | 1,628 |  |  | $ | 955 |  |  | $ | 4,659 |  |  | $ | 1,721 |  |  | $ | 1,382 |  |  | $ | 753 |  |  | $ | 3,856 |
The following table presents the company’s total revenue disaggregated by end markets and by revenue type:
| Three Months Ended |  | Nine Months Ended
| July 31 |  | July 31
| 2021 |  | 2020 |  | 2021 |  | 2020
| (in millions) |  |  |  |
Revenue by End Markets |  |  |  |  |  |  |
Pharmaceutical and Biopharmaceutical | $ | 576 |  |  | $ | 440 |  |  | $ | 1,628 |  |  | $ | 1,263 |
Chemical and Energy | 334 |  |  | 260 |  |  | 976 |  |  | 839 |
Diagnostics and Clinical | 242 |  |  | 178 |  |  | 691 |  |  | 572 |
Food | 143 |  |  | 123 |  |  | 449 |  |  | 367 |
Academia and Government | 138 |  |  | 119 |  |  | 423 |  |  | 375 |
Environmental and Forensics | 153 |  |  | 141 |  |  | 492 |  |  | 440 |
Total | $ | 1,586 |  |  | $ | 1,261 |  |  | $ | 4,659 |  |  | $ | 3,856 |
Revenue by Type |  |  |  |  |  |  |
Instrumentation | $ | 640 |  |  | $ | 526 |  |  | $ | 1,953 |  |  | $ | 1,610 |
Non-instrumentation and other | 946 |  |  | 735 |  |  | 2,706 |  |  | 2,246 |
Total | $ | 1,586 |  |  | $ | 1,261 |  |  | $ | 4,659 |  |  | $ | 3,856 |
Contract Liabilities and Changes in Balances | The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the nine months ended July 31, 2021:
|  | Contract Liabilities
|  | (in millions)
Ending balance as of October 31, 2020 |  | $ | 446 |
Net revenue deferred in the period |  | 361 |
Revenue recognized that was included in the contract liability balance at the beginning of the period |  | (322) |
Change in deferrals from customer cash advances, net of revenue recognized |  | 26 |
Currency translation and other adjustments |  | 4 |
Ending balance as of July 31, 2021 |  | $ | 515 |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration